• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Lett Appl Microbiol . Comparison of hemagglutination inhibition and hemagglutinin pseudovirus neutralization titers in relation to protection agains

tetano

Editor, Senior Moderator
Lett Appl Microbiol


. 2021 May 24.
doi: 10.1111/lam.13513. Online ahead of print.
Comparison of hemagglutination inhibition and hemagglutinin pseudovirus neutralization titers in relation to protection against influenza in a mouse model


Yin Huang[SUP] 1 [/SUP], Zhengshi Lin[SUP] 2 [/SUP], Wei Wang[SUP] 2 [/SUP], Carol Weiss[SUP] 2 [/SUP], Hang Xie[SUP] 2 [/SUP], Richard A Forshee[SUP] 1 [/SUP]



Affiliations

Abstract

The hemagglutination inhibition (HI) test has long been used as a standard measure of antibody response for inactivated influenza vaccines. However, the HI test has limitations, such as insensitivity when using some H3N2 virus strains and failure to detect neutralizing antibodies that target regions distant from the receptor binding site. We therefore examined a hemagglutinin pseudovirus neutralization (PVN) test as a possible supplement or alternative to the HI test. We evaluated the association of HI or PVN titers with protection against influenza infection in mice based on morbidity (where the illness was defined as 25% body weight loss). We assessed this relationship using dose-response models incorporating HI or PVN titers as a variable. The morbidity was correlated with the pre-exposure titers and such a correlation was well described by a modified dose-response model. The mathematical modeling suggests PVN titers consistently show a stronger association with in vivo protection as compared to HI titers in mice. Given our findings, the PVN test warrants further investigation as a tool for evaluating antibody responses to influenza vaccines containing hemagglutinin. The resulting models may also be useful for analyzing human clinical data to identify potentially protective antibody titers against influenza illness.
 
Back
Top Bottom